Indivior Pharmaceuticals, Inc. (INDV) Guidance & Earnings Results
On 2026-08-03 Indivior Pharmaceuticals, Inc. raised guidance: "FY26 Net Revenue raised to $1,295-1,365M from $1,215-1,285M; FY26 Total SUBLOCADE Net Revenue raised to $1,010-1,050M from $950-990M; FY26 Non-GAAP Operating Expenses unchanged at $430-450M; FY26 Adjusted EBITDA raised…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
INDVIndivior Pharmaceuticals, Inc.Follow INDV — free
—
Price chart with a free account
- Market cap
- 4.1B
- P/E TTM
- 12.4
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 3 Aug 26 | Raised | FY26 Net Revenue raised to $1,295-1,365M from $1,215-1,285M; FY26 Total SUBLOCADE Net Revenue raised to $1,010-1,050M from $950-990M; FY26 Non-GAAP Operating Expenses unchanged at $430-450M; FY26 Adjusted EBITDA raised to $700-740M from $620-660M. · full year |
| 30 Apr 26 | Raised | FY2026 net revenue raised to $1.215-1.285B, SUBLOCADE growth 13% YoY, Adjusted EBITDA growth 50% YoY · full year |
| 26 Feb 26 | Reaffirmed | FY2026 net revenue $1,125M-$1,195M; SUBLOCADE $905M-$945M; Adjusted EBITDA $535M-$575M · full year |
| 30 Oct 25 | Raised | FY2025 net revenue raised to $1.18-$1.22B, adjusted EBITDA to $400-$420M · full year |
| 31 Jul 25 | Raised | FY25 net revenue raised to $1.03-1.08B from $955M-$1.025B; SUBLOCADE NR raised to $765-785M from $725-765M; Adjusted EBITDA raised to $275-300M from $220-260M; Non-GAAP gross margin unchanged low-mid 80s%; Non-GAAP SG&A unchanged $500-510M; Non-GAAP R&D unchanged $85-90M. · full year |
Indivior Pharmaceuticals, Inc. — questions
- What guidance did Indivior Pharmaceuticals, Inc. give?
- On 2026-08-03: "FY26 Net Revenue raised to $1,295-1,365M from $1,215-1,285M; FY26 Total SUBLOCADE Net Revenue raised to $1,010-1,050M from $950-990M; FY26 Non-GAAP Operating Expenses unchanged at $430-450M; FY26 Adjusted EBITDA raised to $700-740M from $620-660M."
- When does Indivior Pharmaceuticals, Inc. report earnings?
- Indivior Pharmaceuticals, Inc.'s next earnings report is expected on 2026-10-29.
Every figure on this page comes from Indivior Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.